Motivational Drivers to Develop Apps for Social Software-Platforms: The Example of Facebook

Online social networks like Facebook or MySpace have enjoyed a formidable success in recent times which is partly due to the provision of software-platforms for the development of social applications through third-party complementors. Consequently, the study of aspects on the role and motivations of these complementors becomes increasingly important. Our empirical study contributes by revealing how the different motivations of social application developers are interrelated and how these motivations influence application developers’ effort intensity on the platform. Drawing on established motivation theories, we develop a theoretical model and test it using empirical data from Facebook application developers. PLS-based structural equation modeling demonstrated that “external rewards” and “status and job opportunity” motives were the dominating motivational drivers. Moreover, we found that external rewards undermine intrinsic motivation, while internalized motives strengthen it. Based on our findings, we discuss practical implications regarding incentive schemes and theoretical implications as starting point for further research

Perceived Software Platform Openness: The Scale and its Impact on Developer Satisfaction

Application developers are of growing importance to ensure that software platforms (e.g. Facebook, Android) gain or maintain a competitive edge. However, despite calls for research to investigate developers’ perspective on platform-centric ecosystems, no research study has been dedicated to identifying the facets that constitute developers’ perception of platform openness. In this paper, we develop a scale of platform openness as perceived by third-party application developers. Using both qualitative and quantitative methods, we conceptualize perceived platform openness as a second-order construct. Empirical evidence from a survey of Android application developers (N=254) support this construct’s validity. Furthermore, we identify perceived platform openness as a major driver of complementors’ overall satisfaction with the platform. Our study thus contributes to a better understanding of platform openness in particular and the management of platform-centric ecosystems in general

Accelerated evidence synthesis in orthopaedics—the roles of natural language processing, expert annotation and large language models

peer reviewedIn an era of electronical medical records, rapidly expanding publication rates of medical knowledge, and large-scale registries, orthopaedics is in a dire need of innovative approaches to facilitate the adoption of the latest knowledge in clinical practice. While machine learning (ML) has been heralded as one solution to many research tasks hampered by previous technological limitations [12], there is an increasing need to direct our attention towards subdomains of ML that are convenient for the extraction of meaningful clinical information stored in medical records. We believe natural language processing (NLP) to be one such domain of ML, with an immense future potential to catalyse rate-limiting steps in orthopaedic research

El primer genoma mitocondrial completo de Diadema antillarum (Diadematoida, Diadematidae)

The mitochondrial genome of the long-spined black sea urchin, Diadema antillarum, was sequenced using Illumina next-generation sequencing technology. The complete mitogenome is 15,708 bp in length, containing two rRNA, 22 tRNA and 13 protein-coding genes, plus a noncoding control region of 133 bp. The nucleotide composition is 18.37% G, 23.79% C, 26.84% A and 30.99% T. The A + T bias is 57.84%. Phylogenetic analysis based on 12 complete mitochondrial genomes of sea urchins, including four species of the family Diadematidae, supported familial monophyly; however, the two Diadema species, D. antillarum and D. setosum were not recovered as sister taxa.El genoma mitocondrial del erizo de mar negro de espinas largas, Diadema antillarum, se secuenció utilizando la tecnología de secuenciación de nueva generación de Illumina. El mitogenoma completo tiene un tamaño de 15,708 pb, que contiene dos ARNr, 22 ARNt y 13 genes codificadores de proteínas, además de una región de control no codificante de 133 pb. La composición de nucleótidos es 18.37% G, 23.79% C, 26.84% A y 30.99% T. El sesgo A+T es del 57.84%. El análisis filogenético basado en 12 genomas mitocondriales completos de erizos de mar, incluyendo cuatro especies de la familia Diadematidae, apoya la monofilia familiar. Sin embargo,  las dos especies de Diadema en este estudio,  D. antillarum y D. setosum no fueron identificadas como taxones hermanos

Abrupt climatic events during the last glacial-interglacial transition in Alaska

Evidence is mounting that abrupt climatic shifts occurred during the last glacial-interglacial transition (LGIT) in the North Atlantic and other regions. However, few high-resolution climatic records of the LGIT exist from the high latitudes of the North Pacific rim. We analyzed lake sediments from southwestern Alaska for biogenic silica, organic carbon, organic nitrogen, diatom assemblages, and compound-specific hydrogen isotopes. Results reveal climatic changes coincident with the Younger Dryas, Intra-Allerod Cold Period, and Pre-Boreal Oscillation. However, major discrepancies exist in the paleoclimate patterns of the Bolling-Allerod interstadial between our data and the GISP2 18O record from Greenland, and causes are uncertain. These data suggest that the North Pacific and North Atlantic experienced similar reversals during climatic warming of the LGIT but that the Bolling-Allerod cooling trend in the GISP2 18O record is probably not a hemispheric or global pattern

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.